Lazard Downgrades American Oriental (AOB) to Hold
More News related to AOB
- American Oriental (AOB) Reports Q3 EPS In-Line
- American Oriental Bioengineering Reports Third Quarter 2008 Financial Results
- American Oriental Bioengineering Announces Participation in November Investor Conferences
- American Oriental Bioengineering, Inc. to Report Third Quarter 2008 Financial Results
- American Oriental Bioengineering Completes Two Acquisitions
More News related to Downgrades
- Post Properties (PPS) Announces Reduction In Quarterly Dividend To 20c, CIO Departure and New Stock Buyback Of Up To $200M
- Roberts Realty Investors (RPI) Increases Stock Repurchase Program
- United American Healthcare (UAHC) Approves $1 Million Stock Buyback
- Quidel Corporation (QDEL) Extends Current Stock Buyback Plan
- Quidel (QDEL) Adds $25M to Buyback Program
Lazard Capital downgrades American Oriental Bioengineering (NYSE: AOB) from Buy to Hold.
American Oriental Bioengineering, Inc., together with its subsidiaries, engages in the development, manufacture, and commercialization of a range of pharmaceutical and healthcare products.
Related Categories
DowngradesStocks Mentioned
+0.40Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
